MB-001 / Mage Biologics - LARVOL DELTA

MB-001-102: A Study to Test a New Drug in Adults With Moderate to Severe Ulcerative Colitis (clinicaltrialsregister.eu) - P1/2 | N=30 | Not yet recruiting | Sponsor: Mage Biologics Inc.

New P1/2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P1/2 | N=100 | Recruiting | Sponsor: Mage Biologics | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - P1/2 | N=100 | Not yet recruiting | Sponsor: Mage Biologics

New P1/2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

MB-001-101: A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Completed | Sponsor: Mage Biologics | Active, not recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Evaluate the Safety of a Single and Multiple Oral Doses of a Biologic Therapy (MB-001) or placebo in Healthy Human Participants (ANZCTR) - P1 | N=48 | Completed | Sponsor: Mage Biologics | Recruiting ➔ Completed

Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

MB-001-101: A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Active, not recruiting | Sponsor: Mage Biologics | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Evaluate the Safety of a Single and Multiple Oral Doses of a Biologic Therapy (MB-001) or placebo in Healthy Human Participants (ANZCTR) - P1 | N=48 | Recruiting | Sponsor: Mage Biologics | Not yet recruiting ➔ Recruiting | Initiation date: May 2024

Enrollment open • Trial initiation date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Evaluate the Safety of a Single and Multiple Oral Doses of a Biologic Therapy (MB-001) or placebo in Healthy Human Participants (ANZCTR) - P1 | N=48 | Not yet recruiting | Sponsor: Mage Biologics

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

MB-001-101: A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Mage Biologics | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Phase 1 Study to Evaluate the Safety of an Oral Biologic in Healthy Participants (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Mage Biologics

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Tillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative Colitis (GlobeNewswire) - "TVM Capital Life Science...Tillotts Pharma...today announced that the companies will jointly invest up to USD 28 million in the newly formed U.S.-based biotechnology company, Mage Biologics Inc...TVM will invest with its fund TVM Life Science Innovation II SCSp ('TVM LSI II') and will provide strategic advice to Mage Bio...Mage Biologics plans to advance to clinical proof of concept a novel, orally administered, humanized monoclonal antibody (mAb) bioengineered for optimal potency and tissue penetration. The mAb has been developed by Tillotts and originated from a discovery collaboration with Swiss biotech company Numab Therapeutics...Initially, the drug will be developed for the treatment of ulcerative colitis. Manufacturing of clinical-grade material is planned to start in 2023, with the goal of filing a clinical trial application in 2024."

Licensing / partnership • Inflammatory Bowel Disease • Ulcerative Colitis